MedPage Today -- ATLANTA -- More than 95% of patients taking a high dose rosuvastatin (Crestor) plus ezetimibe (Zetia) combination reached low-density lipoprotein (LDL) goals of less than 100 mg/dl -- a significant improvement over a high-dose combination of simvastatin/ezetimibe (Vytorin), researchers said here.
